Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 278

1.

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, Johnson AJ.

Blood. 2014 Feb 20;123(8):1207-13. doi: 10.1182/blood-2013-07-515361. Epub 2013 Dec 5.

2.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC.

Blood. 2011 Jun 9;117(23):6287-96. doi: 10.1182/blood-2011-01-328484. Epub 2011 Mar 21.

3.

Targeting BTK through microRNA in chronic lymphocytic leukemia.

Bottoni A, Rizzotto L, Lai TH, Liu C, Smith LL, Mantel R, Reiff S, El-Gamal D, Larkin K, Johnson AJ, Lapalombella R, Lehman A, Plunkett W, Byrd JC, Blachly JS, Woyach JA, Sampath D.

Blood. 2016 Dec 29;128(26):3101-3112. doi: 10.1182/blood-2016-07-727750. Epub 2016 Oct 17.

PMID:
27756747
4.

Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.

Ren L, Campbell A, Fang H, Gautam S, Elavazhagan S, Fatehchand K, Mehta P, Stiff A, Reader BF, Mo X, Byrd JC, Carson WE 3rd, Butchar JP, Tridandapani S.

J Biol Chem. 2016 Feb 5;291(6):3043-52. doi: 10.1074/jbc.M115.687251. Epub 2015 Dec 1.

5.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC.

N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28.

6.

Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.

Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL.

Leukemia. 2015 Apr;29(4):895-900. doi: 10.1038/leu.2014.263. Epub 2014 Sep 5.

PMID:
25189416
7.

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA.

Blood. 2012 Feb 2;119(5):1182-9. doi: 10.1182/blood-2011-10-386417. Epub 2011 Dec 16.

8.
9.

Ibrutinib treatment of CLL: the cancer fights back.

Young RM, Staudt LM.

Cancer Cell. 2014 Jul 14;26(1):11-3. doi: 10.1016/j.ccr.2014.06.023.

10.

Bruton Kinase Inhibitors in Chronic Lymphocytic Leukemia.

Gozzetti A, Candi V, Brambilla CZ, Papini G, Fabbri A, Bocchia M.

Anticancer Agents Med Chem. 2017;17(8):1040-1045. doi: 10.2174/1871520616666160928153342. Review.

PMID:
27697038
11.

Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib.

Guo A, Lu P, Galanina N, Nabhan C, Smith SM, Coleman M, Wang YL.

Oncotarget. 2016 Jan 26;7(4):4598-610. doi: 10.18632/oncotarget.6727.

12.

Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.

Dias AL, Jain D.

Cardiovasc Hematol Agents Med Chem. 2013 Dec;11(4):265-71. Review.

13.

Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.

Brown JR.

Curr Hematol Malig Rep. 2013 Mar;8(1):1-6. doi: 10.1007/s11899-012-0147-9. Review.

14.

Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia.

Rushworth SA, Murray MY, Zaitseva L, Bowles KM, MacEwan DJ.

Blood. 2014 Feb 20;123(8):1229-38. doi: 10.1182/blood-2013-06-511154. Epub 2013 Dec 4.

15.

BTK inhibitors in chronic lymphocytic leukemia: a glimpse to the future.

Spaargaren M, de Rooij MF, Kater AP, Eldering E.

Oncogene. 2015 May 7;34(19):2426-36. doi: 10.1038/onc.2014.181. Epub 2014 Jun 23. Review.

PMID:
24954503
16.

Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.

Kaur V, Swami A.

Ann Hematol. 2017 Jul;96(7):1175-1184. doi: 10.1007/s00277-017-2973-2. Epub 2017 Mar 24. Review.

PMID:
28342031
17.

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.

Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, Liu M, Buggy JJ, Furman RR, Wang YL.

Leukemia. 2014 Mar;28(3):649-57. doi: 10.1038/leu.2013.358. Epub 2013 Nov 25.

PMID:
24270740
18.

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA.

JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218.

19.

Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors.

Sinha S, Boysen J, Nelson M, Secreto C, Warner SL, Bearss DJ, Lesnick C, Shanafelt TD, Kay NE, Ghosh AK.

Clin Cancer Res. 2015 May 1;21(9):2115-26. doi: 10.1158/1078-0432.CCR-14-1892. Epub 2015 Feb 11.

20.

Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.

Cervantes-Gomez F, Lamothe B, Woyach JA, Wierda WG, Keating MJ, Balakrishnan K, Gandhi V.

Clin Cancer Res. 2015 Aug 15;21(16):3705-15. doi: 10.1158/1078-0432.CCR-14-2809. Epub 2015 Mar 31.

Supplemental Content

Support Center